Name (Synonyms) | Correlation | |
---|---|---|
drug1185 | SARS-CoV-2 diagnostic rapid test Wiki | 1.00 |
drug591 | Hydroxychloroquine Wiki | 0.11 |
drug1016 | Placebo Wiki | 0.08 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The aim of the SARS-CoV-2-CZ-Preval study is to quantify the prevalence of individuals with a history of SARS-CoV-2 coronavirus infection in the Czech population, except for those diagnosed with COVID-19 by methods based on direct detection of SARS-CoV- 2, including individuals with a subclinical course of the disease.
Description: Statistically, the primary objective is formulated as an estimate of the cumulative prevalence of SARS-CoV-2 positive individuals in geographically defined subpopulations of the Czech Republic with declared reliability of +/- 2%. For this primary objective, the required sample size in individual geographical cohorts is calculated. The positivity of SARS-CoV-2 individuals who have not been diagnosed with COVID-19 by a standard route of the detection will be assessed by the presence of specific IgM or IgG antibodies in the blood (antibody tests).
Measure: Estimation of the actual prevalence of SARS-CoV-2 positive persons in the Czech Republic. Time: May 2020Description: The proportion of SARS-CoV-2 positive persons who, according to the questionnaire, will not report any or minimal symptoms in the anamnesis.
Measure: Estimation of the proportion of people with a subclinical course of the disease Time: May 2020Description: The estimation will be calculated according to the prevalence of the disease in the population after excluding contraindications to blood donation (age, health status, etc.).
Measure: Estimation of the proportion of persons suitable for the donation of convalescent plasma Time: May 2020